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A 14-year-old girl with HIV infection and subcutaneous Kaposi's sarcoma (KS) received thalido-
mide therapy for oral ulcers, resulting in regression of KS lesions, disappearance of KS-associated
herpesvirus (KSHV) DNA from blood, and reduced viral load in tumor tissue. Administration of
granulocyte colony-stimulating factor resulted in clinical exacerbation of KS and reappearance of
KSHV DNA in blood.
Kaposi's sarcoma (KS), a proliferative disease of endothelial
cell origin, is a common AIDS-defining illness in HIV-infected
adults. It also occurs infrequently in children with vertically
acquired HTV infection [1]. As current therapies, including
chemotherapy, systemic TFN-a, and local radiotherapy, have a
limited effect [2], there is a need for alternative therapeutic
approaches.
See the editorial by Levine on pages 504-5.
A novel herpesvirus has been recently described as a possible
cause of KS. In the United States, Chang and colleagues iso-
lated two unique DNA fragments from a KS skin lesion and
showed that they were from a previously unidentified y2 her-
pesvirus, provisionally termed Kaposi's sarcoma-associated
herpesvirus (KSHV) [3]. Further investigations showed an as-
sociation between detectable KSHV DNA in peripheral blood
and KS and, more importantly, that the detection of KSHV
DNA in peripheral blood from HIV-infected individuals pre-
dicted progression to KS [4].
We report the case of a 14-year-old girl with vertically ac-
quired HTV infection and KS whose tumor clinically regressed
while she was receiving treatment with thalidomide for oral
ulcers [5]. Regression of the tumor was paralleled by the disap-
pearance ofKSHV DNA from peripheral blood and a reduction
of viral load in tumor tissue.
Case Report
A 14-year-old girl with vertically acquired HIV infection
who immigrated from Zaire to Switzerland developed subcuta-
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neous nodular lesions on both arms, the left upper leg, and the
right eyelid. Histologic examination of specimens from the
lesions revealed proliferation of spindle-shaped cells and of
vascular structures with large endothelial cells; on the basis of
these findings, the diagnosis of KS was made. She had been
well until the age of 9 years, when she experienced the first
of several episodes of pneumonia. She subsequently developed
various HTV-associated diseases, including recurrent oral can-
didiasis, lymphocytic interstitial pneumonitis, and Pneumo-
cystis carinii pneumonia (one episode). Her CD4+ cell count
had been 0/ILL for 14 months before the diagnosis of KS was
made.
At the time that the diagnosis of KS was made, her therapy
included co-trimoxazole, oral amphotericin B, didanosine, and
monthly iv immunoglobulin infusions; this therapy remained
unchanged except for the temporary use of antibiotics to treat
acute infections. She did not receive cytotoxic or immuno-
modulating chemotherapy or radiotherapy. The KS lesions in-
creased slowly in number and size over a 4-month period.
At the age of 14.3 years the patient developed painful oral
ulcers. Histologic examination of specimens from the ulcers
as well as conventional cultures for bacteria, mycobacteria,
fungi, and viruses revealed no infectious cause. After topical
and systemic corticosteroid therapy failed, therapy with thalido-
mide was started at a dose of 3 mg/(kg· d) [5]. During 3 weeks
of treatment with thalidomide, a coincidental decrease in the
size of the existing KS-associated lesions was noted, and no
new lesions developed. Therapy with thalidomide was therefore
continued after the oral ulcers resolved.
Two months later, no new lesions appeared and the number
of lesions decreased from 29 to 13. Treatment with thalidomide
was successfully augmented by local radiotherapy to two digital
nodes, which caused restricted distal interphalangeal joint mo-
bility, and to the right upper lid (for cosmetic reasons).
The patient's course of therapy was further complicated by
Candida albicans septicemia that required iv therapy with am-
photericin B together with granulocyte colony-stimulating fac-
tor (G-CSF) because of severe neutropenia. This therapy was
associated with an increase in the size of the remaining KS
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Table 1. Detection of Kaposi's sarcoma-associated herpesvirus
DNA in the blood and tumor tissue of an HIV-infected girl before
and during treatment with thalidomide.
Detectable copies of
KSHV DNA per
KSHVDNA human genome
in peripheral
Age (therapy) blood Tumor Nontumor
14 y, 14 mo
(prethalidomide) Positive 10 0.01
14 y, 7 mo
(thalidomide) ND 0.1 <0.0001
14 y, 8 mo
(thalidomide
plus G-CSF) Positive NA <0.0001
14y, 11 mo
(thalidomide) ND NA NA
NOTE. G-CSF granulocyte colony-stimulating factor; KSHV
Kaposi's sarcoma-associated herpesvirus; NA = not analyzed; ND = not
detected.
lesions. Therapy with G-CSF was stopped, and the size of the
tumor decreased clinically. As of this writing, the patient has
been receiving thalidomide therapy for 7 months. Her tumor
bulk is stable and she has not experienced any adverse effects
from thalidomide.
Methods
Detection ofKSHV. We examined blood, tumor tissue, and
healthy skin for the presence of KSHV DNA with use ofnested
PCR amplification (previously described in [4]). DNA was
extracted from the tissue samples by digestion with 10% SDS
buffer containing 10 mMTris-HCI, 10 mMEDTA, and 10 mM
NaCl, together with proteinase K at 1 ILg/mL, and tested for
KSHV DNA and human DNA. This test involved amplification
of the human single copy gene encoding pyruvate dehydroge-
nase by PCR, which has been shown to have a sensitivity of
a single input copy (data not shown). Quantification of human
and KSHV DNA was performed by endpoint dilution. To con-
trol for PCR inhibitors, samples that did not contain KSHV
DNA were spiked with known amounts of virus genome.
HIV viral load. Quantitative measurement of HIV viral
RNA was performed on stored serum samples with use of a
commercial PCR test (Amplicor HIV Monitor, Roche Diagnos-
tic Systems, Branchburg, NJ); the manufacturer's instructions
were followed.
Results
KSHV DNA was detected in blood, tumor tissue, and healthy
skin before treatment with thalidomide was started (Table 1).
In contrast, blood obtained 3 months after thalidomide therapy
was started contained no detectable KSHV DNA, and tumor
tissue showed an approximate 100-fold decrease in viral load.
However, 6 days after starting G-CSF therapy, KSHV DNA
again became detectable in blood and was associated with a
clinical increase in tumor bulk. At this time, viral DNA was
still undetectable in healthy tissue. Tumor tissue was not avail-
able for analysis. Blood taken 3 months after G-CSF therapy
was stopped contained no detectable KSHV DNA. No gross
histological changes were noted in tumor tissues obtained be-
fore thalidomide therapy was started vs. in those obtained 3
months later.
Two stored serum samples were available for retrospective
quantitative measurement of HIV viral load. One sample,
drawn when the patient was 14 years old (before therapy with
didanosine was started), contained 106,441 copies ofHIV RNA
per mL. The other sample, obtained when the patient was 14.6
years old (3 months after thalidomide treatment was started),
harbored 9,563 copies of HIV RNA per mL.
Discussion
The observation of clinical regression of KS lesions in a
patient with vertically acquired HIV infection who was receiv-
ing therapy with thalidomide raises interesting questions, espe-
cially as this regression was paralleled by a virological re-
sponse, with KSHV DNA becoming undetectable in blood and
being reduced in tumor tissue. Although the clinical assessment
of KS tumor bulk is imprecise and the observations were made
in a single patient, the clinical and virological effects are bio-
logically plausible.
Thalidomide inhibits monocyte TNF -a by degrading
TNF-a mRNA [6]. It also inhibits angiogenesis induced by
basic fibroblast growth factor, which might explain its terato-
genic potential [7]. Furthermore, thalidomide induces T helper
cell type 2 (i.e., antiinflammatory) and inhibits T helper cell
type 1 (i.e., proinflammatory) cytokine production [8]. TNF-
a, basic fibroblast growth factor, and T helper cell type I
cytokines such as IFN -'Y stimulate spindle cell transformation
and mitosis of KS cells [9]. This finding could explain the
clinical effect of thalidomide on our patient's KS lesions.
In contrast, G-CSF stimulates proliferation of human endo-
thelial cells [10] and may, therefore, have counterbalanced the
effect of thalidomide, resulting in a rapid increase in KS tumor
bulk when the patient started receiving G-CSF therapy. This
clinical deterioration was paralleled by the reappearance of
KSHV DNA in peripheral blood (table 1).
There is no other plausible explanation for the apparent re-
gression and enlargement ofKS lesions in our patient following
administration of thalidomide and G-CSF since other therapy
was unchanged throughout the period of observation, the pa-
tient did not receive acyclovir, and the level of immunodefi-
ciency remained unaltered. It is not clear whether thalidomide
has a direct effect on KSHV DNA, resulting in changes in the
viral load. In vitro studies using KS cell lines [11] and KSHV-
containing cell lines [12] may help to elucidate this question.
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Our patient's HIV viral load while she was receiving treat-
ment with thalidomide was less than 10% of the viral load
before thalidomide therapy was started. However, determina-
tion of the viral load was done retrospectively on stored serum
and not on plasma because the latter was not available. Since
the patient also started receiving didanosine therapy during the
interval between collection of specimens, the reduction of HIV
load cannot be attributed solely to thalidomide treatment. Nev-
ertheless, thalidomide has been shown to inhibit replication of
HIV in vitro and in vivo [13].
Although this case suggests that thalidomide may be effica-
cious in the treatment ofa patient with HIV-related KS, conven-
tional chemotherapy, radiotherapy, and IFN-a should remain
first-line therapeutic options. However, we suggest that thalido-
mide should be further studied as a therapeutic agent for the
treatment of HIV-induced KS and that its use may be justified
in patients with disseminated KS who are considered unsuitable
for or who are unable to tolerate conventional therapeutic inter-
ventions.
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